INT52180

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1995
Last Reported 2010
Negated 4
Speculated 1
Reported most in Body
Documents 38
Total Number 39
Disease Relevance 23.16
Pain Relevance 6.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Anatomy Link Frequency
muscle 1
nasal 1
Aes (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Lamotrigine 5 100.00 Very High Very High Very High
Gabapentin 4 100.00 Very High Very High Very High
Ziconotide 720 99.98 Very High Very High Very High
Neuropathic pain 42 99.68 Very High Very High Very High
depression 32 99.16 Very High Very High Very High
headache 26 98.24 Very High Very High Very High
Analgesic 70 97.98 Very High Very High Very High
nud 7 97.20 Very High Very High Very High
Inflammation 102 96.60 Very High Very High Very High
Opioid 71 96.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Vomiting 70 100.00 Very High Very High Very High
Cognitive Disorder 56 100.00 Very High Very High Very High
Confusion 55 100.00 Very High Very High Very High
Diarrhoea 12 100.00 Very High Very High Very High
Gastrointestinal Disease 4 100.00 Very High Very High Very High
Flatulence 1 100.00 Very High Very High Very High
Muscular Spasm 3 99.96 Very High Very High Very High
Phobia 1 99.90 Very High Very High Very High
Inflammatory Bowel Disease 37 99.84 Very High Very High Very High
Neuropathic Pain 44 99.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We did not find a significant statistical association of AEs and mortality.
AEs Neg (not) Binding (association) of
1) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.08 Pain Relevance 0
Thus, the association of AEs with poor outcomes may be due to confounding [4].
AEs Binding (association) of
2) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.07 Pain Relevance 0
AEs were strongly associated with time to hospital discharge, even after adjusting for other important clinical factors (Table 4b).
AEs Binding (associated) of
3) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.39 Pain Relevance 0
CONCLUSIONS: FPNS use for BTCP was associated with AEs, typical of opioids, with no evidence of nasal toxicity.
AEs Binding (associated) of in nasal
4) Confidence 0.42 Published 2010 Journal J Opioid Manag Section Body Doc Link 21046929 Disease Relevance 0 Pain Relevance 0
We determined whether AEs were associated with time to in-hospital death or time to hospital discharge using Cox proportional hazards modelling.
AEs Binding (associated) of associated with death
5) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.28 Pain Relevance 0
AEs were not associated with time to in-hospital death, either before or after adjusting for factors also associated with hospital mortality (Table 4a).
AEs Binding (associated) of associated with death
6) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.46 Pain Relevance 0
Thus, we might find a diminished association between AEs and outcomes if we studied patients treated in other areas of the hospital.
AEs Binding (association) of
7) Confidence 0.42 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.23 Pain Relevance 0.14
Anti-siplizumab antibodies were detected after exposure to siplizumab; however, there was no evidence of an association between antibody development and AEs.
AEs Neg (no) Binding (association) of
8) Confidence 0.32 Published 2010 Journal Int. J. Dermatol. Section Abstract Doc Link 20618506 Disease Relevance 0.51 Pain Relevance 0.26
While such a rating scheme is descriptive, it does not inform regarding downstream impact of the AEs.
AEs Binding (impact) of
9) Confidence 0.32 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0 Pain Relevance 0
Those new AEs already marketed in Portugal (Vigabatrin), soon to be (Lamotrigine, Oxcarbazepine) or available abroad only (Gabapentin, Zonisamide) are review with special emphasis on their pharmacokinetic profile, side effects, interaction with other AEs, and clinical use.
AEs Binding (interaction) of associated with lamotrigine and gabapentin
10) Confidence 0.31 Published 1995 Journal Acta Med Port Section Abstract Doc Link 7747611 Disease Relevance 0.17 Pain Relevance 0.29
Furthermore, this potential bias would not influence the measured association of the AEs with length of stay and mortality.


AEs Neg (not) Binding (association) of
11) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.20 Pain Relevance 0.14
We determined the association of AEs in the ICU with time to death and time to hospital discharge using multivariable survival analysis models.


AEs Spec (determined) Binding (association) of associated with death
12) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Abstract Doc Link PMC2621200 Disease Relevance 0.39 Pain Relevance 0
We estimated that AEs were independently associated with an average increase in hospital length of stay of 31 days.
AEs Binding (associated) of
13) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.09 Pain Relevance 0
Third, as previously mentioned, we had a relatively small sample size, increasing the possibility that we failed to detect true associations between preventable AEs and important outcomes.
AEs Binding (associations) of
14) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.24 Pain Relevance 0.17
We studied this population because ICU patients have well developed risk adjustment instruments and a sufficiently high rate of AEs and death to facilitate identifying an association between AEs and outcomes.


AEs Binding (association) of associated with death
15) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.25 Pain Relevance 0
The proportions of AEs associated with the use of Estratest (575 events; 66.6%) and Estratest HS (288 events; 33.4%) were commensurate with the proportions of individual reports of adverse experiences for the two formulations (369 reports [65.0%] and 199 reports [35.0%], respectively).
AEs Binding (associated) of
16) Confidence 0.31 Published 1997 Journal Clin Ther Section Abstract Doc Link 9385494 Disease Relevance 0.09 Pain Relevance 0
Larger studies are needed to conclusively measure the association between preventable AEs and patient outcomes.



AEs Binding (association) of
17) Confidence 0.31 Published 2008 Journal BMC Health Serv Res Section Abstract Doc Link PMC2621200 Disease Relevance 0.27 Pain Relevance 0
Nonocular AEs associated with any particular system organ class were observed in ?
AEs Binding (associated) of
18) Confidence 0.20 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2938279 Disease Relevance 1.14 Pain Relevance 0.20
Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs with bazedoxifene was similar to that seen with placebo.
AEs Binding (incidence) of
19) Confidence 0.19 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2908075 Disease Relevance 0.41 Pain Relevance 0
Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs with bazedoxifene was similar to that seen with placebo.
AEs Binding (incidence) of
20) Confidence 0.19 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2908075 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox